• MM2 Designing Computer Models to Convey Cost-Effectiveness Analyses Results

    May 1, 1998, 00:00

  • PMH15 Development of A Self-Administered Outcome Measure for Use in An Outpatient Population of Individuals with Schizophrenia

    May 1, 1998, 00:00

  • PHB9 Use of Centralized Pharmacy Records in A Managed Care Organization to Determine Effect of Educational Material on Hormone Replacement Therapy Patient Compliance

    May 1, 1998, 00:00

  • PMD17 Surveillance of A New Drug in the United Kingdom

    May 1, 1998, 00:00

  • DA5 Disease State Management Tracker- Implementing, Tracking, And Evaluating Clinical Pathways And Outcomes

    May 1, 1998, 00:00

  • PCV2 An Analysis of the Economics of Hypertension

    May 1, 1998, 00:00

  • CC1 Socioeconomic Efficiency of Prophylaxis of Exacerbations with N-Acetylcysteine in Patients with Chronic Bronchitis

    May 1, 1998, 00:00

  • MHC4 Testing The Reliability of Generic Quality-of-Life Measures in the Study of Multiple Sclerosis

    May 1, 1998, 00:00

  • CVA5 Effect of Compliance on Health And Economic Outcomes- Role of Conjugated Estrogen on Depression And Cardiovascular Disorders

    May 1, 1998, 00:00

  • MGB6 Formulary Impact Decision Modeling in HMG-COA Reductase Inhibitors

    May 1, 1998, 00:00

  • PGD2 The Economic Implications of Decreased Patient Adherence to Co-Prescribed Diclofenac And Misoprostol (CORX-DM) Relative to A Single-Tablet Formulation of Diclofenac/Misoprostol (STF-D/M)

    May 1, 1998, 00:00

  • GIR1 Economic And Clinical Outcomes Models for the Evaluation of Drug Therapy Strategies in Treatment of Gerd

    May 1, 1998, 00:00

  • PCV6 Development of A Decision-Analytic Model of Stroke Care in us And Europe

    May 1, 1998, 00:00

  • MM5 Comparing Computerized Options in Pharmacoeconomics- Spreadsheets, Decision Trees, And Educational Tools- An Open Workshop for Demonstrating Software

    May 1, 1998, 00:00

  • PMD14 Vox Populi- Stated Preferences for Pharmaceutical Innovations

    May 1, 1998, 00:00

  • DM2 Dissemination of Pharmacoeconomic Results to Managed Care Organizations

    May 1, 1998, 00:00

  • MHB1 Treatment Choice And the Incidence And Economic Intensity of Hospital Inpatient Use by Depressed Patients

    May 1, 1998, 00:00

  • PMH4 Quality of Life And Adverse Reactions in Depressed Patients Receiving Antidepressant Drugs

    May 1, 1998, 00:00

  • PCV4 Empirical Analysis of the Cost-Efficiency of HMG-COA Reductase Inhibitors

    May 1, 1998, 00:00

  • MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation- Canada

    May 1, 1998, 00:00

  • PCV10 Medical And Economic Outcomes in Patients Treated with Diltiazem or Digoxin for Atrial Fibrillation- A Database Analysis

    May 1, 1998, 00:00

  • PMH8 Duration of Continuous Therapy Between Atypical And Typical Antipsychotics

    May 1, 1998, 00:00

  • GIR3 Cost-Effectiveness of Proton Pump Inhibitors in Gastric ULCER

    May 1, 1998, 00:00

  • PMH17 Utilization Patterns of Antidepressant Medications in A Patient Population Served by A Primary Care Medical Group

    May 1, 1998, 00:00

  • PCV14 Nonparametric Analysis of Cost-Effectiveness Ratios of Pravastatin in Primary Prevention of Cardiovascular Disease

    May 1, 1998, 00:00

  • PGD4 Cost-Effectiveness Analysis of Screening of Type II Diabetes Mellitus in Nonpregnant Adults

    May 1, 1998, 00:00

  • PCV16 Smoking Related Costs in the United States

    May 1, 1998, 00:00

  • MGA4 A Retrospective Approach to Evaluate Qaly- Estimation of Health Utility Index from the SF-36 in A Managed Care Population

    May 1, 1998, 00:00

  • PMD7 The Value of Medicines- Is There Enough Economic Evidence?

    May 1, 1998, 00:00

  • MHA1 The Economic Burden of Alzheimers Disease to Medicaid in California (MEDI-CAL)

    May 1, 1998, 00:00

  • PHB4 The Responsiveness of Disease-Specific And Generic Health Measures to Changes in the Severity of Rheumatoid Arthritis And to Treatment

    May 1, 1998, 00:00

  • MHC1 A Model of Primary Care Treatment of Major Depressive Disorder

    May 1, 1998, 00:00

  • PCV1 Factors Influencing the Decision to Treat Serum Lipid Disorders by Drug Therapy in the Primary Care Venue

    May 1, 1998, 00:00

  • PMD16 Implication of Preventing Disease on Life Years Gained (LYG)

    May 1, 1998, 00:00

  • DM3 Outcomes Research in Medication Use- HCFAS Health Care Quality Improvement Program

    May 1, 1998, 00:00

  • MHB6 Medical And Economic Relevance of Screening of Stroke Risk by Employees

    May 1, 1998, 00:00

  • PHB10 Quality of Life And Pharmacoeconomic Aspects of Hormone Replacement Therapy in Post-Menopausal Women-A Canadian Randomized Trial

    May 1, 1998, 00:00

  • CVB1 Cost of Italian Hypertensive Patient- A Feasibility Study from the Pandora Project

    May 1, 1998, 00:00

  • PHB2 SF-12 Osteoarthritis-Specific Health Index- Development And Validation

    May 1, 1998, 00:00

  • PMH16 A Health Policy Analysis of Pharmacotherapy for Major Depressive Disorder in Europe And the Americas

    May 1, 1998, 00:00

  • PMH10 Selective Serotonin Reuptake Inhibitor Utilization Patterns- Consistency Across Research Designs

    May 1, 1998, 00:00

  • DA1 Using Medication History to Measure Indication Bias

    May 1, 1998, 00:00

  • PIC5 Cost-Effectiveness Analysis of Piperacillin-Tazobactam Versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections

    May 1, 1998, 00:00

  • ID2 Willingness to Pay for HIV Prevention- A Study of High-And Low-Risk Groups

    May 1, 1998, 00:00

  • PIC3 Colorectal Cancer Screening- Cost-Effectiveness Analysis from An Italian Viewpoint

    May 1, 1998, 00:00

  • MHB4 Comparison of Standard Gamble, Time Trade-Off, And Visual Analog Scale Scores for Hypothetical Stroke Health States Using A Computer-Based Program

    May 1, 1998, 00:00

  • MGA3 A New Paradigm for Assessing Health-Related Quality of Life- A Social-Clinical Model

    May 1, 1998, 00:00

  • DA7 Prospective, Naturalistic Outcomes Measurement- The Schizophrenia Care And Assessment Program (SCAP)

    May 1, 1998, 00:00

  • DA3 Using Community Pharmacies to Conduct Outcomes Research

    May 1, 1998, 00:00

  • PCV17 Lipid Therapy And Cardiovascular Disease- How Many Americans Should be Treated?

    May 1, 1998, 00:00

  • PMD2 The Effect of the Louisiana Medicaid Lock-in on Prescription Drug Utilization And Expenditures

    May 1, 1998, 00:00

  • MGB1 Poor Adherence to Hypertension Treatment Guidelines- An Analysis of Therapeutic Choices

    May 1, 1998, 00:00

  • MHA2 Cost Impact of Using Olanzapine at A Veterans Affairs Medical Center

    May 1, 1998, 00:00

  • PGD13 Does the Duration of Pulmonary Rehabilitation Affect the Magnitude of Patient Response?

    May 1, 1998, 00:00

  • PGD14 A Health Economic Analysis of Fluticasone Propionate, Budesonide, And Beclomethasone Dipropionate for the Treatment of Moderate to Severe Asthma

    May 1, 1998, 00:00

  • PHB11 Determining Minimally Important Changes (MIC) in Rheumatoid Arthritis (RA) Functional Status

    May 1, 1998, 00:00

  • PCV7 Economic Evaluation of Torasimide in Congestive Heart Failure in Germany

    May 1, 1998, 00:00

  • PMD5 Prescription Medication Use in Older Americans

    May 1, 1998, 00:00

  • CVB4 In-Hospital Survival of Congestive Heart Failure Patients Treated with Dobutamine or Milrinone

    May 1, 1998, 00:00

  • MGB2 The Utilization And Costs of Prescription Drugs in A Texas Medicaid Managed Care Pilot Program

    May 1, 1998, 00:00

  • PIC2 Socioeconomic Relevance of Inpatient Treatment of Intra-Abdominal Infections with Tazobactam/Piperacillin 0.5 g/4.0 g in Comparison with Imipenem/Cilastatin

    May 1, 1998, 00:00

  • CC2 Cost of Preventable Adverse Drug Events in Emergency Department Patients

    May 1, 1998, 00:00

  • PMD4 Outcomes Research Interests of A Community Pharmacist Research Network

    May 1, 1998, 00:00

  • MHB2 Medical Costs of Venlafaxine Versus Tricyclic or Tetracyclic Antidepressant Therapy After Switching from Selective Serotonin Reuptake Inhibitors

    May 1, 1998, 00:00

  • PCV5 Pharmaceutical Costs of Patient Non-Adherence to Lipid-Lowering Drug Therapy

    May 1, 1998, 00:00

  • PMD15 An Unbiased Method of Pharmaceutical Cost Analysis

    May 1, 1998, 00:00

  • MGA5 Health Utilities Index- Further Evidence of Responsiveness

    May 1, 1998, 00:00

  • MHC2 Medical And Economic Outcomes of Noncompliance with Dilantin in Adult Medicaid Epileptics

    May 1, 1998, 00:00

  • PGD12 Cost of Prescription Drugs And Cost of Treatment Failure for Sinusitis

    May 1, 1998, 00:00

  • PMD11 Use of Administrative Databases in Saskatchewan, Canada, for Pharmacoeconomic and Outcomes Research

    May 1, 1998, 00:00

  • PMH6 Economic Outcomes of Antidepressant Use in A Managed Care Organization

    May 1, 1998, 00:00

  • CM4 Use of UB-92S And Medicare Cost Reports in A Large, Multi-Center Randomized Trial- The Pursuit Experience

    May 1, 1998, 00:00

  • CM3 Multivariable Methods for Measuring Treatment Costs in Randomized Trials

    May 1, 1998, 00:00

  • MHB5 Changes in Sexual Function And Bother in Men Treated for Prostate Cancer- Results from the Capsure Database

    May 1, 1998, 00:00
  • «
  • 181
  • 182 (current)